Literature DB >> 10779416

Role of SUMO-1-modified PML in nuclear body formation.

S Zhong1, S Müller, S Ronchetti, P S Freemont, A Dejean, P P Pandolfi.   

Abstract

The tumor-suppressive promyelocytic leukemia (PML) protein of acute promyelocytic leukemia (APL) has served as one of the defining components of a class of distinctive nuclear bodies (NBs). PML is delocalized from NBs in APL cells and is degraded in cells infected by several viruses. In these cells, NBs are disrupted, leading to the aberrant localization of NB proteins. These results have suggested a critical role for the NB in immune response and tumor suppression and raised the question of whether PML is crucial for the formation or stability of NB. In addition, PML is, among other proteins, covalently modified by SUMO-1. However, the functional relevance of this modification is unclear. Here, we show in primary PML(-/-) cells of various histologic origins, that in the absence of PML, several NB proteins such as Sp100, CBP, ISG20, Daxx, and SUMO-1 fail to accumulate in the NB and acquire aberrant localization patterns. Transfection of PML in PML(-/-) cells causes the relocalization of NB proteins. By contrast, a PML mutant that can no longer be modified by SUMO-1 fails to do so and displays an aberrant nuclear localization pattern. Therefore, PML is required for the proper formation of the NB. Conjugation to SUMO-1 is a prerequisite for PML to exert this function. These data shed new light on both the mechanisms underlying the formation of the NBs and the pathogenesis of APL. (Blood. 2000;95:2748-2752)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779416

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  216 in total

1.  Self-association of coilin reveals a common theme in nuclear body localization.

Authors:  M D Hebert; A G Matera
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

2.  Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Authors:  Christine Wasylyk; Sophie E Schlumberger; Paola Criqui-Filipe; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.

Authors:  P Bell; P M Lieberman; G G Maul
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  EBNA3C coactivation with EBNA2 requires a SUMO homology domain.

Authors:  Adam Rosendorff; Diego Illanes; Gregory David; Jeffrey Lin; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication.

Authors:  Michael Nevels; Wolfram Brune; Thomas Shenk
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  SUMO modified proteins localize to the XY body of pachytene spermatocytes.

Authors:  Richard S Rogers; Amy Inselman; Mary Ann Handel; Michael J Matunis
Journal:  Chromosoma       Date:  2004-09-03       Impact factor: 4.316

7.  Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2.

Authors:  Satoshi Tashiro; Akihiko Muto; Keiji Tanimoto; Haruka Tsuchiya; Hiroshi Suzuki; Hideto Hoshino; Minoru Yoshida; Joachim Walter; Kazuhiko Igarashi
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

Review 8.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 10.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.